Allergy Therapeutics plc

LSE AGY.L

Allergy Therapeutics plc Total Assets for the year ending June 30, 2024: USD 82.05 M

Allergy Therapeutics plc Total Assets is USD 82.05 M for the year ending June 30, 2024, a -3.18% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.
  • Allergy Therapeutics plc Total Assets for the year ending June 30, 2023 was USD 84.75 M, a -4.58% change year over year.
  • Allergy Therapeutics plc Total Assets for the year ending June 30, 2022 was USD 88.82 M, a -27.08% change year over year.
  • Allergy Therapeutics plc Total Assets for the year ending June 30, 2021 was USD 121.81 M, a 13.93% change year over year.
  • Allergy Therapeutics plc Total Assets for the year ending June 30, 2020 was USD 106.91 M, a 22.95% change year over year.
Key data
Date Total Assets Current Liabilities Total Non-Current Liabilities Shareholders' Equity
Market news
Loading...
LSE: AGY.L

Allergy Therapeutics plc

CEO Mr. Manuel Llobet
IPO Date Oct. 11, 2004
Location United Kingdom
Headquarters Dominion Way
Employees 612
Sector Health Care
Industries
Description

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

StockViz Staff

January 15, 2025

Any question? Send us an email